The association and clinical significance of hematological biomarkers in ankylosing spondylitis
- PMID: 40328909
- PMCID: PMC12056196
- DOI: 10.1038/s41598-025-99274-4
The association and clinical significance of hematological biomarkers in ankylosing spondylitis
Abstract
Ankylosing spondylitis (AS) is a prevalent type of arthritis presented by inflammation in the vertebrae joints accounting for high disability and morbidity rates globally. Although there is limited research exploring efficient diagnostic tools for this condition, a timely and precise diagnosis is required. This case-control study aimed to examine the association and clinical significance of inflammatory markers derived from whole blood cell count when used as indicators of AS and to assess the reliability of these indicators in a clinical setting. A logistic regression was conducted to evaluate the diagnostic potential of inflammatory biomarkers when used independently and in combination with other indices. Pearson's correlation test was used to analyze normally distributed data and Spearman's correlation coefficient was used for non-normally distributed data. A total of 171 AS patients were included in this study. There was no statistical difference in age between the groups (P > 0.05). There were significant variations in the following counts among groups counts: SII, WBC, RDW, ESR, CRP, neutrophil, lymphocyte, platelet, dNLR, and MLR, counts (P < 0.05), with WBC, CRP, ESR, platelets, lymphocyte, neutrophils, dNLR, MLR, and SII being significantly elevated in the AS patients group (P < 0.05). Based on the BASDAI score, 45 patients were assigned to the active group and 126 patients to the remission group. These two groups showed no statistical difference regarding age, RDW, WBC, platelets, neutrophils, monocytes, PLR, and dNLR (P > 0.05). SIRI, NLR, PLR, dNLR, NMLR, and SII may serve as valuable biomarkers of AS in a clinical setting.
Keywords: Ankylosing spondylitis; Biomarkers; Complete blood count; Diagnostic; Inflammatory markers.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Ethics approval and consent to participate: Data utilized was obtained through prior informed consent and ethical approval and all procedures were performed following the 1964 Declaration of Helsinki and its later amendments and access was approved by First Affiliated Hospital of Anhui Medical University.
Figures
References
-
- Mauro, D. et al. Ankylosing spondylitis: An autoimmune or autoinflammatory disease?. Nat. Rev. Rheumatol.17(7), 387–404. 10.1038/s41584-021-00625-y (2021). - PubMed
-
- Taurog, J. D., Chhabra, A. & Colbert, R. A. Ankylosing spondylitis and axial spondyloarthritis. N. Engl. J. Med.374(26), 2563–2574. 10.1056/nejmra1406182 (2016). - PubMed
-
- Sariyildiz, A., Benlidayi, I. C., Turk, I., Zengin Acemoglu, S. S. & Unal, I. Evaluation of the relationship between blood cell markers and inflammation, disease activity, and general health status in ankylosing spondylitis. Rev. Assoc. Med. Bras.69(10), 1–7. 10.1590/1806-9282.20230722 (2023). - PMC - PubMed
-
- Danve, A. Thoracic manifestations of ankylosing spondylitis, inflammatory bowel disease, and relapsing polychondritis. Clin. Chest Med.40(3), 599–608. 10.1016/j.ccm.2019.05.006 (2019). - PubMed
-
- Atzeni, F., Corda, M., Sarzi-Puttini, P., Caso, F. & Turiel, M. From old to new cardiovascular complications in ankylosing spondylitis. Isr. Med. Assoc. J.19(8), 506–509 (2017). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
